Metropolitan Life Insurance Co. NY trimmed its stake in shares of OraSure Technologies (NASDAQ:OSUR) by 51.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 17,889 shares of the medical instruments supplier’s stock after selling 18,839 shares during the quarter. Metropolitan Life Insurance Co. NY’s holdings in OraSure Technologies were worth $337,000 as of its most recent SEC filing.
Several other large investors also recently added to or reduced their stakes in the stock. Millennium Management LLC raised its stake in shares of OraSure Technologies by 87.9% during the 4th quarter. Millennium Management LLC now owns 1,624,216 shares of the medical instruments supplier’s stock valued at $30,633,000 after purchasing an additional 759,958 shares during the period. Teachers Advisors LLC raised its stake in shares of OraSure Technologies by 9.0% during the 4th quarter. Teachers Advisors LLC now owns 965,464 shares of the medical instruments supplier’s stock valued at $18,209,000 after purchasing an additional 79,886 shares during the period. Raymond James & Associates raised its stake in shares of OraSure Technologies by 84.4% during the 4th quarter. Raymond James & Associates now owns 41,007 shares of the medical instruments supplier’s stock valued at $773,000 after purchasing an additional 18,771 shares during the period. Teachers Retirement System of The State of Kentucky raised its stake in shares of OraSure Technologies by 216.0% during the 4th quarter. Teachers Retirement System of The State of Kentucky now owns 61,300 shares of the medical instruments supplier’s stock valued at $1,156,000 after purchasing an additional 41,900 shares during the period. Finally, Goldman Sachs Group Inc. increased its stake in OraSure Technologies by 13.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 153,352 shares of the medical instruments supplier’s stock worth $2,892,000 after acquiring an additional 17,929 shares during the last quarter. Institutional investors own 92.86% of the company’s stock.
In other news, EVP Brian Smith sold 20,000 shares of the company’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $17.97, for a total value of $359,400.00. Following the completion of the transaction, the executive vice president now directly owns 28,075 shares in the company, valued at approximately $504,507.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Stephen S. Phd Tang sold 23,333 shares of the company’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $17.97, for a total value of $419,294.01. Following the completion of the transaction, the director now owns 59,749 shares of the company’s stock, valued at $1,073,689.53. The disclosure for this sale can be found here. 2.90% of the stock is currently owned by corporate insiders.
OraSure Technologies (NASDAQ:OSUR) last announced its earnings results on Wednesday, February 7th. The medical instruments supplier reported $0.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.11 by $0.01. OraSure Technologies had a return on equity of 13.09% and a net margin of 18.52%. The business had revenue of $52.00 million for the quarter, compared to analyst estimates of $50.20 million. During the same period in the prior year, the company earned $0.13 EPS. The company’s quarterly revenue was up 46.5% compared to the same quarter last year. equities analysts predict that OraSure Technologies will post 0.29 earnings per share for the current fiscal year.
A number of brokerages have weighed in on OSUR. BidaskClub upgraded OraSure Technologies from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 20th. Canaccord Genuity restated a “buy” rating and issued a $24.00 target price on shares of OraSure Technologies in a research note on Friday, February 2nd. Zacks Investment Research upgraded OraSure Technologies from a “sell” rating to a “hold” rating in a research note on Tuesday, January 9th. Finally, ValuEngine upgraded OraSure Technologies from a “hold” rating to a “buy” rating in a research note on Friday, March 2nd. One analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $22.25.
TRADEMARK VIOLATION WARNING: This news story was originally posted by Week Herald and is the property of of Week Herald. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://weekherald.com/2018/04/19/metropolitan-life-insurance-co-ny-has-337000-position-in-orasure-technologies-osur.html.
About OraSure Technologies
OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.